Some Essential Facts About Illumina

Shares of Health Care sector company Illumina moved -0.2% today, and are now trading at a price of $207.67. The large-cap stock's daily volume was 46,722 compared to its average volume of 1,242,701. The S&P 500 index returned a 1.0% performance.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is based in San Diego and has 11,500 full time employees. Its market capitalization is $32,832,626,688.

19 analysts are following Illumina and have set target prices ranging from $150.0 to $336.0 per share. On average, they have given the company a rating of hold. At today's prices, ILMN is trading -13.08% away from its average analyst target price of $238.92 per share.

Over the last year, ILMN's share price has increased by 9.9%, which represents a difference of -6.0% when compared to the S&P 500. The stock's 52 week high is $248.87 per share whereas its 52 week low is $173.45. Illumina's average free cash flow over the last 4 years has been $767.0 Million, but they have been decreasing at an average rate of -21.9%. This may prove a challenge to the long term sustainability of the stock's upwards trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2022-12-31 392,000 -466,000 392,000 -28.07
2021-12-31 545,000 -208,000 545,000 -49.54
2020-12-31 1,080,000 -189,000 1,080,000 2.76
2019-12-31 1,051,000 -209,000 1,051,000 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS